EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus

Qinghua Wang, Fan Jiang, Yulong Xu, Yuyang Lei, Li Zhang, Xiaodong Sun

Clinical Pharmacokinetics · 2025

DOI: 10.1007/s40262-025-01570-9 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Pharmacokinetics, 2025. Verfasst von Qinghua Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Innogen Pharmaceutical Technology Co., Ltd., No. 501, Building 10, 299 Bi Bo Road, Shanghai, 201203, China. qh_wang@fudan.edu.cn. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide 1, Recombinant Fusion Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: This study was sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Efsubaglutide alfa is a novel glucagon-like peptide-1 receptor agonist composed of dual GLP-1 molecules fused with the fragment crystallizable (Fc) region of human immunoglobulin G2. It is designed for the treatment of type 2 diabetes mellitus (T2DM) and metabolic diseases. OBJECTIVES: This study aimed to quantitatively describe the exposure-response (E-R) relationship between efsubaglutide alfa exposure and efficacy and safety endpoints in patients with T2DM and to assess the impact of baseline characteristics on the E-R relationship. METHODS: An E-R analysis was conducted using data from 465 drug-naïve participants with T2DM in a phase IIb/III trial (YN011-301), which included a 24-week double-blind period followed by a 28-week open-label period. Participants received once-weekly subcutaneous injections of efsubaglutide alfa 1 mg, 2 mg, or 3 mg or placebo. Regression analysis was performed against the steady-state pharmacokinetic exposure, including steady state peak concentration (Cmax,ss), steady state minimum concentration (Cmin,ss), steady state average concentration (Cavg,ss), and their logarithms. RESULTS: The median age was 51.0 years, and the mean baseline glycated hemoglobin (HbA1c) was 8.71%. At weeks 24 and 52, reductions in HbA1c, fasting plasma glucose, area under the concentration-time curve for glucose during the mixed-meal tolerance test, body weight, waist circumference, and body mass index correlated positively with drug exposure. The E-R model indicated that a 10-fold increase in Cmin,ss led to a 1.150% decrease in HbA1c at week 24. Baseline HbA1c, age, and neutralizing anti-drug antibody influenced the E-R relationship for HbA1c. Safety analysis showed a positive correlation between drug exposure and the incidence of treatment-related adverse events, particularly nausea and diarrhea, with tolerance developing over time. CONCLUSIONS: Efsubaglutide alfa demonstrates a strong E-R relationship for glycemic control and weight reduction in drug-naïve participants with T2DM. The extended half-life and favorable safety profile of efsubaglutide alfa make it well-suited for once weekly or biweekly monotherapy in patients with newly diagnosed T2DM. TRIAL REGISTRATION: The trial was registered at Clinicaltrials.gov (identifier: NCT04994288).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsGlucagon-Like Peptide 1Recombinant Fusion ProteinsHumansMiddle AgedFemaleMaleDouble-Blind MethodAdultAgedGlycated HemoglobinBlood GlucoseDose-Response Relationship, DrugGlucagon-Like Peptide-1 Receptor AgonistsImmunoglobulin Fc Fragments

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide 1Glycated HemoglobinBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Innogen Pharmaceutical Technology Co., Ltd., No. 501, Building 10, 299 Bi Bo Road, Shanghai, 201203, China. qh_wang@fudan.edu.cn.
  • Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China. qh_wang@fudan.edu.cn.
  • Innogen Pharmaceutical Technology Co., Ltd., No. 501, Building 10, 299 Bi Bo Road, Shanghai, 201203, China.
  • Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China.
  • Department of Endocrinology and Metabolism, Affiliated Hospital of Shandong Second Medical University, Weifang, 261031, China.

Förderung

  • This study was sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd.

Zitieren

APA

Wang, Q., Jiang, F., Xu, Y., Lei, Y., Zhang, L., & Sun, X. (2025). Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01570-9

Vancouver

Wang Q, Jiang F, Xu Y, Lei Y, Zhang L, Sun X. Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus. Clinical Pharmacokinetics. 2025. doi:10.1007/s40262-025-01570-9

BibTeX
@article{Wang2025,
  author = {Wang, Qinghua and Jiang, Fan and Xu, Yulong and Lei, Yuyang and Zhang, Li and Sun, Xiaodong},
  title = {Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus},
  journal = {Clinical Pharmacokinetics},
  year = {2025},
  doi = {10.1007/s40262-025-01570-9}
}
Kostenlos starten →